Intellia Q3 Loss Widens to $127.5 Million as Launch Costs Rise
Intellia Therapeutics reported third-quarter results on November 5, 2026, showing a net loss of $127.5 million, up from $101.3 million in the third quarter of 2025. Higher commercial-launch spending and lower collaboration revenue offset a reduction in research costs, while an investment-valuation swing added to the bottom-line decline. For the quarter ended September 30, 2026, collaboration revenue fell to $7.2 million from $13.8 million, primarily because of reduced revenue from Regeneron…